N/A N=39 Inflammation and Corticosteroid Responsiveness in Severe Asthma
Asthma
Primary: Lung Function FEV1 — 84.9; 59.9 % of predicted — p=0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=850 A Study of Omalizumab (Xolair) in Subjects With Moderate to Severe Persistent Asthma (EXTRA)
Asthma
Primary: Rate of Asthma Exacerbations Over the 48 Week Treatment Period — 0.88; 0.66 exacerbation/patient-week
Phase 4 N=36 Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists
Allergic Asthma
Primary: Change From Baseline in Total Subepithelial Eosinophils at the End of Week 78 (End of Treatment) — -5.807; -5.890; 1.555; -5.626 cells/mm^2
Phase 2 N=502 A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe Asthma
Asthma
Primary: Reduction in Rate of Asthma Exacerbations — 0.74; 0.47; 0.58; 0.42 Number of asthma exacerbations per year — p=0.0049
Phase 3 N=300 A Safety and Efficacy Study of Mepolizumab in Subjects With Severe Asthma
Asthma
Primary: Rate of Clinically Significant Exacerbations of Asthma — 0.45; 1.31 Exacerbations per year — p=<0.001
Phase 3 N=135 Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma
Asthma
Primary: Number of Participants With the Indicated Percent Reduction From Baseline in Oral Corticosteroid (OCS) Dose During Weeks 20 to 24 While Maintaining Asthma Control — 7…
Phase 2 N=550 Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma
Asthma
Primary: Annualized Asthma Exacerbation Rate (AER) Through Week 52 — 0.72; 0.27; 0.20; 0.23 events per person-year — p=<0.001
Phase 3 N=400 Study to Evaluate Tezepelumab in Adults With Severe Uncontrolled Asthma
Asthma
Primary: Annual Asthma Exacerbation Rate (AERR) — 0.42; 1.63 Events per year — p=<0.001
Phase 3 N=1,061 Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma
Asthma
Primary: Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma — 0.93; 2.10 events per year — p=<0.001
Phase 2 N=776 An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma
Asthma
Primary: Absolute Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 12: High Eosinophils -Intent to Treat (HEos-ITT) Population — 1.86; 1.77; 1.8; 1.87…
Phase 3 N=894 Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
Asthma
Primary: Rate of Moderate-to-severe Asthma Exacerbations During the 52-week Treatment Period in High Eosinophils Subpopulation — 0.97; 0.77; 0.93 events/year — p=0.800
Phase 2 N=480 GB001 in Adult Subjects With Moderate to Severe Asthma
Asthma
Primary: Proportion of Participants Who Experience Worsening of Asthma by Week 24 — 0.658; 0.567; 0.568; 0.557 proportion of participants — p=0.1425
Phase 2 N=32 Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe Asthma
Asthma
Primary: Number of Patients Reported to Have Adverse Events — 11; 6; 11 participants
Phase 3 N=551 Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control
Asthma
Primary: Mean Change From Baseline (BL) in St. George's Respiratory Questionnaire (SGRQ) Score at Week 24 — -7.9; -15.6 Scores on a scale — p=<0.001
Phase 2 N=118 Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma
Asthma
Primary: Change From Baseline in Forced Expiratory Volume in One Second (FEV1) — 0.043; 0.016 Liters — p=0.7374
Phase 2 N=15 A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Severe, Refractory Asthma
Severe, Refractory Asthma · Airway Inflammation · Airflow Obstruction
Primary: 16 Weeks - Juniper Asthma Quality of Life Questionnaire (AQLQ) Score — 4.7; 4.6 units on a scale
Phase 3 N=877 Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
Asthma
Primary: Rate of Moderate-to-severe Asthma Exacerbations During the 52-week Treatment Period in High Eosinophils Subpopulation — 0.73; 0.76; 1.06 Events/year — p=0.059
Phase 3 N=196 Clinical Study to Evaluate the Efficacy and Safety of VR506 Using a New Inhaler for the Treatment of Asthma
Asthma
Primary: Mean Prednisone/Prednisolone Dose for Analysis (PDA) at End of Study (Week 16) — 4.55; 4.31; 3.97 mg — p=0.772
Phase 2 N=616 Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma
Asthma
Primary: Number of Clinically Significant Exacerbations of Asthma Per Year — 2.40; 1.24; 1.46; 1.15 Exacerbations per year — p=<0.001
Phase 2 N=64 Roflumilast Plus Montelukast in Adults With Severe Asthma
Asthma
Primary: Change From Baseline in Pre-Dose (Trough) Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) — 0.18; 0.08 liters — p=0.013
Phase 4 N=50 Improving Asthma Control in the Real World: A Systematic Approach to Improving Dulera Adherence
Asthma
Primary: Asthma Control — 1.857; 1.592; 1.792; 1.578 units on a scale — p=0.046
Phase 3 N=576 Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma
Asthma
Primary: Number of Clinically Significant Exacerbations of Asthma Per Year — 1.74; 0.93; 0.83 Number of exacerbations per year — p=<0.001
Phase 2 N=21 Personalized Treatment Algorithms for Difficult-to-treat Asthma
Asthma in Children
Primary: Change in Composite Asthma Severity Index (CASI) — 5; 5; 5 score on a scale — p=0.52
Phase 3 N=295 Steroids In Eosinophil Negative Asthma
Asthma
Primary: Pairwise Comparison of Treatments Based on Composite Measure Using Treatment Failures, Asthma Control Days, and Percent Predicted FEV1. — 74; 35; 56; 12 Participants…
Phase 2 N=165 Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma
Asthma
Primary: Percentage of Participants With Loss of Asthma Control Over Weeks 0-16 — 81; 67 Percentage of participants
Phase 2 N=65 A Study to Establish the Efficacy of QBX258 in Patients With Moderate to Severe Asthma
Asthma
Primary: Change From Baseline in Asthma Control Questionnaire (ACQ) Score — -0.513; 0.001 score on a scale — p=0.005
Phase 2 N=104 Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma
Asthma
Primary: Percentage of Participants With Asthma Exacerbation — 44.2; 5.8; 19.2; 1.9 percentage of participants — p=<0.0001
Phase 4 N=406 Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma
Asthma
Primary: Persistency of Response and Non-response as Based on Investigator's Global Evaluation of Treatment Effectiveness (GETE) — 190; 29; 187; 28 participants
Phase 4 N=81 SERETIDE 100/50 bd (Twice Daily) Versus FLIXOTIDE 100 bd As Initial Maintenance Therapy In Moderate Asthma In Adults
Asthma
Primary: Change From Baseline in Mean Morning Peak Expiratory Flow (PEF) Over Weeks 5-12 — 59.21; 50.98 Liters per minute (L/min) — p=0.683
Phase 3 N=616 Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy
Persistent Allergic Asthma
Primary: Change From Baseline in Mean Morning Peak Expiratory Flow (PEF) Following the 24-week Treatment Period — 27.03; 18.18 L/min